STAT3-IN-46 

STAT3-IN-46 is a selective and orally active inhibitor of signal transducer and activator of transcription 3 (STAT3) (K_D = 323.3 nM). STAT3-IN-46 directly binds to the SH2 domain of the STAT3 and inhibits IL-6/JAK/STAT3 signaling pathway (IC₅₀ = 0.87 μM) and downregulates c-Myc and Bcl-2 levels. STAT3-IN-46 can be used for the research of cancer, such as triple-negative breast cancer^[1].

STAT3-IN-46 (Compound W36) 在 MDA-MB-231 和 MDA-MB-468 细胞中显示出抗增殖活性，其 IC₅₀ 值分别为 0.61 和 0.65 μM^[1]。
STAT3-IN-46 在 HEK293 和 HK2 细胞中显示出最小的细胞毒性作用，其 IC₅₀ 值分别为 1.87 和 1.73 μM^[1]。
STAT3-IN-46 在 HEK-Blue-IL-6 细胞中抑制 IL-6/JAK/STAT3 信号通路，IC₅₀ 值为 0.87 μM^[1]。
STAT3-IN-46 (2.5-10 μM, 6-12 h) 抑制 MDA-MB-231 和 MDA-MB-468 细胞中磷酸化 STAT3 的水平^[1]。
STAT3-IN-46 (2.5-10 μM, 24 h) 可下调 MDA-MB-231 和 MDA-MB-468 细胞中 c-Myc 和 Bcl-2 的水平^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

STAT3-IN-46 (Compound W36) (腹腔注射 7.5-10 mg/kg 或口服 100 mg/kg，每日一次，持续 16 天) 可抑制 MDA-MB-231 异种移植小鼠模型中的肿瘤生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

564.68

C₃₁H₂₉FN₈S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang R, et al. Discovery of potent and selective STAT3 inhibitors against triple-negative breast cancer. Eur J Med Chem. 2025 Nov 15;298:118020.  [Content Brief]